Caseware UK (AP4) 2023.0.135 2023.0.135 2024-04-302024-04-302023-05-01false12truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 05791558 2023-05-01 2024-04-30 05791558 2022-05-01 2023-04-30 05791558 2024-04-30 05791558 2023-04-30 05791558 2022-05-01 05791558 c:Director1 2023-05-01 2024-04-30 05791558 d:ComputerEquipment 2023-05-01 2024-04-30 05791558 d:ComputerEquipment 2024-04-30 05791558 d:ComputerEquipment 2023-04-30 05791558 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 05791558 d:CurrentFinancialInstruments 2024-04-30 05791558 d:CurrentFinancialInstruments 2023-04-30 05791558 d:CurrentFinancialInstruments d:WithinOneYear 2024-04-30 05791558 d:CurrentFinancialInstruments d:WithinOneYear 2023-04-30 05791558 d:ShareCapital 2024-04-30 05791558 d:ShareCapital 2023-04-30 05791558 d:RetainedEarningsAccumulatedLosses 2024-04-30 05791558 d:RetainedEarningsAccumulatedLosses 2023-04-30 05791558 c:OrdinaryShareClass1 2023-05-01 2024-04-30 05791558 c:OrdinaryShareClass1 2024-04-30 05791558 c:OrdinaryShareClass1 2023-04-30 05791558 c:FRS102 2023-05-01 2024-04-30 05791558 c:AuditExempt-NoAccountantsReport 2023-05-01 2024-04-30 05791558 c:FullAccounts 2023-05-01 2024-04-30 05791558 c:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 05791558 2 2023-05-01 2024-04-30 05791558 d:AcceleratedTaxDepreciationDeferredTax 2024-04-30 05791558 d:AcceleratedTaxDepreciationDeferredTax 2023-04-30 05791558 d:RetirementBenefitObligationsDeferredTax 2024-04-30 05791558 d:RetirementBenefitObligationsDeferredTax 2023-04-30 05791558 e:PoundSterling 2023-05-01 2024-04-30 xbrli:shares iso4217:GBP xbrli:pure
Registered number: 05791558









CAMBRIDGE MEDCHEM CONSULTING LIMITED

UNAUDITED

FINANCIAL STATEMENTS
INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 APRIL 2024

 
CAMBRIDGE MEDCHEM CONSULTING LIMITED
REGISTERED NUMBER: 05791558

BALANCE SHEET
AS AT 30 APRIL 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
7,557
5,805

Current assets
  

Debtors: amounts falling due within one year
 5 
21,003
10,627

Cash at bank
  
125,582
95,940

  
146,585
106,567

Current liabilities
  

Creditors: amounts falling due within one year
 6 
(13,250)
(8,409)

Net current assets
  
 
 
133,335
 
 
98,158

Provisions for liabilities
  

Deferred tax
 7 
(1,874)
(1,437)

Net assets
  
139,018
102,526


Capital and reserves
  

Called up share capital 
 8 
2
2

Profit and loss account
  
139,016
102,524

  
139,018
102,526


Page 1

 
CAMBRIDGE MEDCHEM CONSULTING LIMITED
REGISTERED NUMBER: 05791558

BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2024

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 






Dr C Swain
Director

Date: 21 December 2024

The notes on pages 3 to 10 form part of these financial statements.

Page 2

 
CAMBRIDGE MEDCHEM CONSULTING LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

1.


GENERAL INFORMATION

Cambridge Medchem Consulting Limited is a private Company limited by shares and incorporated in England and Wales within the United Kingdom. The address of the registered office is 3 Morleys Place, Sawston, Cambridgeshire, CB22 3TG. This Company is not part of a group.

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Income and Retained Earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

Page 3

 
CAMBRIDGE MEDCHEM CONSULTING LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.3

REVENUE

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.4

INTEREST INCOME

Interest income is recognised in profit or loss using the effective interest method.

 
2.5

FINANCE COSTS

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

PENSIONS

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 
CAMBRIDGE MEDCHEM CONSULTING LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.7

CURRENT AND DEFERRED TAXATION

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Page 5

 
CAMBRIDGE MEDCHEM CONSULTING LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.8

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment
-
33%
straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.9

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.10

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.11

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.12

PROVISIONS FOR LIABILITIES

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

Page 6

 
CAMBRIDGE MEDCHEM CONSULTING LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.13

FINANCIAL INSTRUMENTS

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance Sheet when the Company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.


3.


EMPLOYEES

The average monthly number of employees, including directors, during the year was 1 (2023 - 2).

Page 7

 
CAMBRIDGE MEDCHEM CONSULTING LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

4.


TANGIBLE FIXED ASSETS





Computer equipment

£



Cost


At 1 May 2023
22,658


Additions
7,603



At 30 April 2024

30,261



Depreciation


At 1 May 2023
16,853


Charge for the year on owned assets
5,851



At 30 April 2024

22,704



Net book value



At 30 April 2024
7,557



At 30 April 2023
5,805

Page 8

 
CAMBRIDGE MEDCHEM CONSULTING LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

5.


DEBTORS

2024
2023
£
£


Trade debtors
16,428
7,729

Other debtors
3,807
2,203

Prepayments
768
695

21,003
10,627



6.


CREDITORS: Amounts falling due within one year

2024
2023
£
£

Trade creditors
426
90

Corporation tax
9,218
6,433

Other creditors
159
147

Accruals
3,447
1,739

13,250
8,409



7.


DEFERRED TAXATION




2024
2023


£

£






At beginning of year
(1,437)
(874)


Charged to profit or loss
(437)
(563)



At end of year
(1,874)
(1,437)

The provision for deferred taxation is made up as follows:

2024
2023
£
£


Accelerated capital allowances
(1,889)
(1,451)

Pension surplus
15
14

(1,874)
(1,437)

Page 9

 
CAMBRIDGE MEDCHEM CONSULTING LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

8.


SHARE CAPITAL

2024
2023
£
£
Allotted, called up and fully paid



2 (2023 - 2) Ordinary shares of £1.00 each
2
2



9.


PENSION COMMITMENTS

The Company operates a defined contributions pension scheme. The assets of the scheme are held
separately from those of the Company in an independently administered fund. The pension cost charge
represents contributions payable by the company to the fund and amounted to £Nil (2023 - £356).
Contributions totalling £139 (2023 - £139) were payable to the fund at the balance sheet date and are
included in creditors.


10.


TRANSACTIONS WITH DIRECTORS

At 1 May 2023 the Director owed the Company £610. During the year they paid expenses on the
Company’s behalf of £520. The Company paid expenses on their behalf of £2,182. At 30 April 2024 £2,272 was owed to the Company. This loan is interest free and repayable on demand. S455 tax has not been provided for as the balance has been repaid within 9 months of the year end


Page 10